Sales Effectiveness

One of the most significant drawbacks for a brand when partnering with individual medical journal platforms is the limitation in reach and scalability they possess.

The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.

AI influencers represent the cutting edge of digital storytelling. But when applied to pharmaceutical marketing, innovation must be balanced with integrity.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

The stakes have never been higher.

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial launch and patient administration is complex and lined with challenges that can impact product success and access.

Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in implementation, the potential unintended consequences, and how these actions could spark the shift to outcomes-based contracting in healthcare.

New technologies and external factors are forcing companies to rethink financial planning and analysis.

Special Guest Opinion: A reimagined regulatory framework for the life sciences is not just pro-investor—it is pro-patient.

35 years of manufacturer rebates by any other name.

Strategies and recommendations for driving value in today’s AI-enhanced prescribing environment.

How fragmented savings undermine transparency, patient savings, and the pharma ecosystem.

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments beginning in August.

Skin cancer is often overlooked by many Americans, who are at elevated risk for being over exposed to the sun in the summer months.

The industry is facing challenges from the new administration that could have serious impacts on everything from market access, pricing, and supply chains.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good practice, it is a strategic imperative.

A Harvard Business School Healthcare Alumni Association Q&A with Aileen Fernandes, Chief Business Officer of Arcellx.

In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.

The film tells the story of a family impacted by the disease and shares the importance of checking to make sure that children are vaccinated against all strains.

Prioritizing deeper customer insights helps life sciences marketers understand how to engage their HCP audiences effectively with the right message.

Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions.

Meeting the growing need and demand for fast information to make optimal and timely treatment decisions.

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

Navigating technology and regulatory shifts in pharma revenue management.

Five steps for organizations in bringing enterprise-level strategies to life.

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer advertising amid policy and government agency overhauls in the US.

The campaign is launching alongside positive news for the company’s Phase 3 trials for a GBS treatment.

Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.